IsoRay, Inc. (NYSEMKT:ISR) rocked the day by reaching over 150%, its high in the last five-year as the company made a statement of accomplishing a major landmark in tumor treatment. On Wednesday, IsoRay announced the successful first-of-its kind treatment of a tumor present in a pediatric patient, which was carried out through multiple Cesium-131 sutured seed meshes. Dr. Anthony Crimaldi at Levine Cancer Institute in Charlotte successfully completed the implant through the use of its Cesium-131 brachytherapy mesh. The patient, who received the treatment was a 12-year-old boy with a kidney tumor. IsoRay, Inc. (NYSEMKT:ISR) stock opened today at $3.08 and is currently trading at $3.21. The stock showed a positive weekly performance of 207.23%.
The company on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. The number of common shares outstanding at December 31, 2013 was 369,391,972. MannKind Corporation (NASDAQ:MNKD) stock opened at $5.84, in current trading session and currently is at $5.92, by gaining 4.07%.The 52 week range of $3.27-$8.70.Company’s market capitalization is $2.24 billion.
BG Medicine, Inc. (Nasdaq: BGMD) announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” to the Company. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood. BG Medicine, Inc. (NASDAQ:BGMD) stock is currently trading at $2.14 .The EPS of the stock is -0.66. Company’s market capitalization is $59.74 million.
Delcath Systems, Inc. (DCTH) announced that it hosted a conference call and webcast on Wednesday, March 12, 2014 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year of 2013 ended December 31, 2013, and provided an update on recent corporate progress. It is a specialty pharmaceutical and medical device company focused on oncology. Delcath Systems, Inc. (NASDAQ:DCTH) stock opened the session at $0.39, and now is at $0.374. The 52 week range of the DCTH stock remained $0.22-$1.93 and the day range was $0.37-$0.42.